Hanmi Pharm. Co., Ltd.
Korea ExchangeTotal Valuation
Hanmi Pharm. Co., Ltd. carries a market capitalization of 5.36T, placing it among publicly traded companies globally. Its enterprise value stands at 6.83T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 5.36T |
| Enterprise Value | 6.83T |
Share Statistics
Hanmi Pharm. Co., Ltd. currently has 12.68M shares outstanding.
| Shares Outstanding | 12.68M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Hanmi Pharm. Co., Ltd. trades at a trailing price-to-earnings ratio of 37.88. The price-to-sales ratio is 4.22, and the price-to-book ratio stands at 7.35.
| PE Ratio | 37.88 |
| PS Ratio | 4.22 |
| PB Ratio | 7.35 |
| P/TBV Ratio | 4.81 |
| P/FCF Ratio | 24.08 |
| P/OCF Ratio | 31.80 |
Enterprise Valuation
On an enterprise value basis, Hanmi Pharm. Co., Ltd. trades at an EV/EBITDA multiple of 17.22 and an EV/FCF ratio of 24.30. The EV/Sales ratio of 4.41 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 17.22 provides insight into valuation relative to core operating earnings.
| EV / Sales | 4.41 |
| EV / EBITDA | 17.22 |
| EV / EBIT | 17.22 |
| EV / FCF | 24.30 |
Financial Position
Hanmi Pharm. Co., Ltd. maintains a current ratio of 1.54, meaning it holds 1.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 28.29, indicating elevated leverage, while an interest coverage ratio of 36.08 demonstrates strong ability to service its debt obligations.
| Current Ratio | 1.54 |
| Quick Ratio | 0.47 |
| Debt / Equity | 28.29 |
| Debt / EBITDA | 1.05 |
| Interest Coverage | 36.08 |
Financial Efficiency
Hanmi Pharm. Co., Ltd. posts a return on equity of 21.14 and a return on invested capital of 19.33.
| Return on Equity (ROE) | 21.14 |
| Return on Assets (ROA) | 8.19 |
| Return on Invested Capital (ROIC) | 19.33 |
| Return on Capital Employed (ROCE) | 11.29 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 2.03 |
Taxes
Over the trailing twelve months, Hanmi Pharm. Co., Ltd. has paid 22.12B in income taxes, reflecting an effective tax rate of 10.25.
| Income Tax | 22.12B |
| Effective Tax Rate | 10.25 |
Stock Price Statistics
Hanmi Pharm. Co., Ltd.'s stock has gained approximately 48.94366% over the past 52 weeks. The 50-day moving average sits at 446,830.00, while the 200-day moving average is 460,230.00.
| Beta (5Y) | N/A |
| 52-Week Price Change | 48.94366% |
| 50-Day Moving Average | 446,830.00 |
| 200-Day Moving Average | 460,230.00 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Hanmi Pharm. Co., Ltd. generated 1.55T in revenue and converted that into 172.44B in net income, yielding earnings per share of 15,262.96. EBITDA reached 396.73B, while operating income came in at 396.73B.
| Revenue | 1.55T |
| Gross Profit | 888.10B |
| Operating Income | 396.73B |
| Pretax Income | 215.68B |
| Net Income | 172.44B |
| EBITDA | 396.73B |
| EBIT | 396.73B |
| Earnings Per Share (EPS) | 15,262.96 |
Balance Sheet
Hanmi Pharm. Co., Ltd. holds 298.38B in cash and equivalents against 418.36B in total debt, resulting in a net debt position of 268.57B. Total book value stands at 888.63B, with working capital of 345.27B providing operational flexibility.
| Cash & Cash Equivalents | 298.38B |
| Total Debt | 418.36B |
| Net Debt | 268.57B |
| Equity (Book Value) | 888.63B |
| Book Value Per Share | 70,065.26 |
| Working Capital | 345.27B |
Cash Flow
Hanmi Pharm. Co., Ltd. produced 205.37B in operating cash flow over the past twelve months. After subtracting -65.86B in capital expenditures, free cash flow totaled 139.51B - equivalent to 11,000.05 per share.
| Operating Cash Flow | 205.37B |
| Capital Expenditures | -65.86B |
| Free Cash Flow | 139.51B |
| FCF Per Share | 11,000.05 |
Margins
Hanmi Pharm. Co., Ltd. operates with a gross margin of 57.32, reflecting its pricing power and cost economics. The operating margin of 25.60 and net profit margin of 11.13 provide insight into operational efficiency.
| Gross Margin | 57.32 |
| Operating Margin | 25.60 |
| Pretax Margin | 13.92 |
| Profit Margin | 11.13 |
| EBITDA Margin | 25.60 |
Dividends & Yields
The company's payout ratio of 6.69 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 1,132.10 |
| Dividend Yield | N/A |
| Payout Ratio | 6.69 |
| Shareholder Yield | 0.32 |
| FCF Yield | 4.15 |
Stock Splits
Hanmi Pharm. Co., Ltd.'s most recent stock split took place on December 27, 2023 with a 50:51 split ratio.
| Last Split Date | 12/27/2023 |
| Split Ratio | 50:51 |
Scores
Hanmi Pharm. Co., Ltd. posts an Altman Z-Score of 7.37, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 7.37 |